Zai Lab Ltd Earnings

The next earnings date for Zai Lab Ltd is March 3, 2026.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Zai Lab Ltd Earnings

Report Date	Estimated Earnings Per Share
03/03/2026	$-0.09

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Zai Lab Ltd Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
11/06/2025	---	$0	100.00%
08/07/2025	---	$-0.37	9.76%
05/06/2025	After Market	$-0.45	17.81%
02/25/2025	Before Market	$-0.80	-26.32%
11/12/2024	Before Market	$-0.42	46.15%
08/06/2024	After Market	$-0.80	-12.68%
05/08/2024	After Market	$-0.50	45.65%
02/27/2024	After Market	$-1	-16.28%
11/07/2023	After Market	$-0.71	31.73%
08/07/2023	After Market	$-1.25	-58.23%
05/09/2023	After Market	$-0.51	46.32%
03/01/2023	After Market	$-0.65	41.44%
11/09/2022	After Market	$-1.68	-34.40%
08/09/2022	After Market	$-1.44	-33.33%
05/10/2022	After Market	$-0.90	25.00%
03/01/2022	After Market	$-2.17	-63.16%
11/09/2021	After Market	$-1.01	14.41%
08/09/2021	After Market	$-1.76	-35.38%
05/10/2021	Before Market	$-2.64	-67.09%
03/01/2021	Before Market	$-0.40	59.78%
12/02/2020	---	$-0.40	0.00%
08/13/2020	Before Market	$-0.99	0.01%
06/03/2020	---	$-0.99	3.89%
03/19/2020	Before Market	$-0.68	-15.25%
11/27/2019	---	$-0.60	5.51%
09/03/2019	After Market	$-0.67	-0.25%
05/29/2019	---	$-0.67	-52.66%
03/07/2019	Before Market	$-2.32	-415.56%
11/28/2018	---	$-0.33	17.50%
08/30/2018	Before Market	$-0.83	-219.23%
05/02/2018	Before Market	$-0.29	-61.11%
11/15/2017	After Market	$-0.21	8.70%
09/21/2017	After Market	$-0.75	---
02/03/2017	---	$-0.76	---
08/04/2016	---	$-0.24	---

More About Zai Lab Ltd

Website

https://www.zailaboratory.com

Country

USA

Full Time Employees

1,869

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is headquartered in Pudong, China.

“Zai Lab Ltd Earnings” Can Refer to the Zai Lab Ltd Earnings Date

Some people say “Zai Lab Ltd earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Zai Lab Ltd position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Zai Lab Ltd Stock on the Earnings Date

If you own Zai Lab Ltd stock (ZLAB) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Zai Lab Ltd might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Zai Lab Ltd shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Zai Lab Ltd Earnings

You can contact us any time if you would like to ask questions about Zai Lab Ltd earnings or anything else related to the stock market.